JP2001501470A - 核酸に基づくアッセイにおけるプローブまたはプライマーとしてのモジュラーオリゴヌクレオチドの使用 - Google Patents
核酸に基づくアッセイにおけるプローブまたはプライマーとしてのモジュラーオリゴヌクレオチドの使用Info
- Publication number
- JP2001501470A JP2001501470A JP10515411A JP51541198A JP2001501470A JP 2001501470 A JP2001501470 A JP 2001501470A JP 10515411 A JP10515411 A JP 10515411A JP 51541198 A JP51541198 A JP 51541198A JP 2001501470 A JP2001501470 A JP 2001501470A
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- modular
- nucleic acid
- module
- capture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 301
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 104
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 103
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 103
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title claims abstract description 75
- 239000000523 sample Substances 0.000 title description 93
- 238000003556 assay Methods 0.000 title description 5
- 238000000034 method Methods 0.000 claims abstract description 109
- 239000002773 nucleotide Substances 0.000 claims abstract description 75
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 75
- 238000009739 binding Methods 0.000 claims abstract description 73
- 230000027455 binding Effects 0.000 claims abstract description 72
- 230000000295 complement effect Effects 0.000 claims abstract description 38
- 238000001514 detection method Methods 0.000 claims abstract description 32
- 238000002955 isolation Methods 0.000 claims abstract description 20
- 238000009396 hybridization Methods 0.000 claims description 27
- 239000007787 solid Substances 0.000 claims description 27
- 238000012163 sequencing technique Methods 0.000 claims description 26
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 24
- 238000013518 transcription Methods 0.000 claims description 13
- 230000035897 transcription Effects 0.000 claims description 13
- 238000005406 washing Methods 0.000 claims description 13
- 108010090804 Streptavidin Proteins 0.000 claims description 12
- 230000003321 amplification Effects 0.000 claims description 12
- 229960002685 biotin Drugs 0.000 claims description 12
- 235000020958 biotin Nutrition 0.000 claims description 12
- 239000011616 biotin Substances 0.000 claims description 12
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 12
- 238000010839 reverse transcription Methods 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 230000003100 immobilizing effect Effects 0.000 claims description 4
- 230000003362 replicative effect Effects 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 88
- 239000011324 bead Substances 0.000 description 42
- 241000711549 Hepacivirus C Species 0.000 description 41
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 38
- 238000003752 polymerase chain reaction Methods 0.000 description 23
- 102000053602 DNA Human genes 0.000 description 22
- 239000000047 product Substances 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 19
- 230000005291 magnetic effect Effects 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 15
- 208000005176 Hepatitis C Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 241000725303 Human immunodeficiency virus Species 0.000 description 12
- 108020004682 Single-Stranded DNA Proteins 0.000 description 12
- 108091093037 Peptide nucleic acid Proteins 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 238000003757 reverse transcription PCR Methods 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 7
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- -1 Where appropriate Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000002205 phenol-chloroform extraction Methods 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102100022653 Histone H1.5 Human genes 0.000 description 1
- 101000899879 Homo sapiens Histone H1.5 Proteins 0.000 description 1
- 101000897979 Homo sapiens Putative spermatid-specific linker histone H1-like protein Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 102100021861 Putative spermatid-specific linker histone H1-like protein Human genes 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000231739 Rutilus rutilus Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- KZSAYVHSKBCVLS-UHFFFAOYSA-K gadolinium(3+) trithiocyanate Chemical compound [Gd+3].[S-]C#N.[S-]C#N.[S-]C#N KZSAYVHSKBCVLS-UHFFFAOYSA-K 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6832—Enhancement of hybridisation reaction
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Seeds, Soups, And Other Foods (AREA)
- Semiconductor Lasers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9620075.3 | 1996-09-26 | ||
| GBGB9620075.3A GB9620075D0 (en) | 1996-09-26 | 1996-09-26 | Method |
| PCT/GB1997/002629 WO1998013522A1 (en) | 1996-09-26 | 1997-09-26 | The use of modular oligonucleotides as probes or primers in nucleic acid based assay |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001501470A true JP2001501470A (ja) | 2001-02-06 |
| JP2001501470A5 JP2001501470A5 (enExample) | 2005-05-12 |
Family
ID=10800518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10515411A Ceased JP2001501470A (ja) | 1996-09-26 | 1997-09-26 | 核酸に基づくアッセイにおけるプローブまたはプライマーとしてのモジュラーオリゴヌクレオチドの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6482592B1 (enExample) |
| EP (1) | EP0928342B1 (enExample) |
| JP (1) | JP2001501470A (enExample) |
| AT (1) | ATE288499T1 (enExample) |
| AU (1) | AU743820B2 (enExample) |
| CA (1) | CA2266749C (enExample) |
| DE (1) | DE69732419T2 (enExample) |
| ES (1) | ES2234031T3 (enExample) |
| GB (1) | GB9620075D0 (enExample) |
| WO (1) | WO1998013522A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9620075D0 (en) | 1996-09-26 | 1996-11-13 | Dynal As | Method |
| US5888778A (en) * | 1997-06-16 | 1999-03-30 | Exact Laboratories, Inc. | High-throughput screening method for identification of genetic mutations or disease-causing microorganisms using segmented primers |
| CA2247545C (en) * | 1998-09-15 | 2008-12-30 | Dynal As | Method of isolation of primer extension products with modular oligonucleotides |
| AU773108B2 (en) * | 1998-09-15 | 2004-05-13 | Dynal Asa | Method of isolation primer extension products with modular oligonucleotides |
| US20010031467A1 (en) * | 1999-12-10 | 2001-10-18 | Johannes Dapprich | Method for selectively isolating a nucleic acid |
| ATE510012T1 (de) * | 2001-03-15 | 2011-06-15 | Univ Aix Marseille Ii | Herstellung von kalibratoren und ihre verwendung zur quantifizierung von besonderen nukleotidsequenzen |
| DE602004021185D1 (de) * | 2003-06-27 | 2009-07-02 | Nanosphere Inc | Auf bio-barcodes beruhender nachweis von zielanalyten |
| US20050095627A1 (en) * | 2003-09-03 | 2005-05-05 | The Salk Institute For Biological Studies | Multiple antigen detection assays and reagents |
| US20060040300A1 (en) * | 2004-08-09 | 2006-02-23 | Generation Biotech, Llc | Method for nucleic acid isolation and amplification |
| US9109256B2 (en) | 2004-10-27 | 2015-08-18 | Esoterix Genetic Laboratories, Llc | Method for monitoring disease progression or recurrence |
| WO2007044071A2 (en) | 2005-04-21 | 2007-04-19 | Exact Sciences Corporation | Analysis of heterogeneous nucleic acid samples |
| US20090263798A1 (en) * | 2006-05-15 | 2009-10-22 | Generation Biotech, Llc | Method For Identification Of Novel Physical Linkage Of Genomic Sequences |
| EP1903117A1 (en) * | 2006-09-22 | 2008-03-26 | Veterinärmedizinische Universität Wien | Methods for the detection of mutations by means of primers that hybridize contiguously |
| US8790916B2 (en) | 2009-05-14 | 2014-07-29 | Genestream, Inc. | Microfluidic method and system for isolating particles from biological fluid |
| US8747084B2 (en) | 2010-07-21 | 2014-06-10 | Aperia Technologies, Inc. | Peristaltic pump |
| EP2809784A4 (en) * | 2012-01-31 | 2015-07-15 | Advanced Liquid Logic Inc | AMPLIFICATION SPREADERS AND PROBES FOR DETECTING HIV-1 |
| US9862995B2 (en) * | 2012-03-13 | 2018-01-09 | Abhijit Ajit Patel | Measurement of nucleic acid variants using highly-multiplexed error-suppressed deep sequencing |
| PL2828103T3 (pl) | 2012-03-20 | 2017-09-29 | Aperia Technologies | System pompowania opon |
| US10144254B2 (en) | 2013-03-12 | 2018-12-04 | Aperia Technologies, Inc. | Tire inflation system |
| US9604157B2 (en) | 2013-03-12 | 2017-03-28 | Aperia Technologies, Inc. | Pump with water management |
| US11453258B2 (en) | 2013-03-12 | 2022-09-27 | Aperia Technologies, Inc. | System for tire inflation |
| ITUA20163413A1 (it) * | 2016-05-13 | 2017-11-13 | Fondazione St Italiano Tecnologia | Reazione di amplificazione di acidi nucleici con primer cooperativi. |
| WO2018048885A1 (en) | 2016-09-06 | 2018-03-15 | Aperia Technologies, Inc. | System for tire inflation |
| US10406869B2 (en) | 2017-11-10 | 2019-09-10 | Aperia Technologies, Inc. | Inflation system |
| US11642920B2 (en) | 2018-11-27 | 2023-05-09 | Aperia Technologies, Inc. | Hub-integrated inflation system |
| US12442364B2 (en) | 2023-12-11 | 2025-10-14 | Aperia Technologies, Inc. | Two-stage pump and method of operation |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05501957A (ja) * | 1990-06-11 | 1993-04-15 | ビオ メリウ | サンドウィッチハイブリッド化技術によるヌクレオチド配列の検出方法 |
| JPH0670799A (ja) * | 1992-08-26 | 1994-03-15 | Toshiba Corp | ハイブリダイゼーション法 |
| JPH06311899A (ja) * | 1993-04-16 | 1994-11-08 | Becton Dickinson & Co | 核酸分析法 |
| JPH0739398A (ja) * | 1993-05-28 | 1995-02-10 | Nippon Flour Mills Co Ltd | 隣接する２種の核酸プローブを用いたｒｎａの検出方法 |
| JPH0759595A (ja) * | 1992-04-30 | 1995-03-07 | Medical Res Council | 結核菌中のイソニアジド抵抗性の迅速検出 |
| WO1996013590A2 (en) * | 1994-10-21 | 1996-05-09 | Innogenetics N.V. | New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents |
| JP2002525076A (ja) * | 1998-09-15 | 2002-08-13 | ダイナル エイエスエイ | モジュラーオリゴヌクレオチドによるプライマーエクステンション産物の単離方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149625A (en) | 1987-08-11 | 1992-09-22 | President And Fellows Of Harvard College | Multiplex analysis of DNA |
| US5030557A (en) | 1987-11-24 | 1991-07-09 | Ml Technology Venture | Means and method for enhancing nucleic acid hybridization |
| US4988617A (en) * | 1988-03-25 | 1991-01-29 | California Institute Of Technology | Method of detecting a nucleotide change in nucleic acids |
| JPH03504199A (ja) * | 1988-05-10 | 1991-09-19 | イー・アイ・デユポン・ド・ネモアース・アンド・コンパニー | 迅速な核酸検出法 |
| EP0426843B1 (en) * | 1989-05-24 | 1995-09-13 | Amoco Corporation | Nucleic acid probes for the detection of neisseria gonorrhoeae |
| JPH0484899A (ja) * | 1990-07-26 | 1992-03-18 | Tosoh Corp | 核酸測定法 |
| US5627032A (en) * | 1990-12-24 | 1997-05-06 | Ulanovsky; Levy | Composite primers for nucleic acids |
| US5428145A (en) | 1991-08-09 | 1995-06-27 | Immuno Japan, Inc. | Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems |
| US5387510A (en) | 1991-10-02 | 1995-02-07 | Eastman Kodak Company | Detection of amplified nucleic acid using secondary capture oligonucleotides and test kit |
| GB9207598D0 (en) | 1992-04-03 | 1992-05-20 | Dynal As | Method of sequencing double stranded dna |
| US5547843A (en) * | 1992-07-17 | 1996-08-20 | Associated Universities, Inc. | Method for promoting specific alignment of short oligonucleotides on nucleic acids |
| CA2170264A1 (en) | 1993-09-10 | 1995-03-16 | Michael W. Konrad | Optical detection of position of oligonucleotides on large dna molecules |
| US5731153A (en) * | 1996-08-26 | 1998-03-24 | The Regents Of The University Of California | Identification of random nucleic acid sequence aberrations using dual capture probes which hybridize to different chromosome regions |
| US5908745A (en) * | 1996-01-16 | 1999-06-01 | University Of Chicago | Use of continuous/contiguous stacking hybridization as a diagnostic tool |
| GB9620075D0 (en) | 1996-09-26 | 1996-11-13 | Dynal As | Method |
| US6124092A (en) | 1996-10-04 | 2000-09-26 | The Perkin-Elmer Corporation | Multiplex polynucleotide capture methods and compositions |
-
1996
- 1996-09-26 GB GBGB9620075.3A patent/GB9620075D0/en active Pending
-
1997
- 1997-09-26 AT AT97942121T patent/ATE288499T1/de not_active IP Right Cessation
- 1997-09-26 ES ES97942121T patent/ES2234031T3/es not_active Expired - Lifetime
- 1997-09-26 EP EP97942121A patent/EP0928342B1/en not_active Expired - Lifetime
- 1997-09-26 JP JP10515411A patent/JP2001501470A/ja not_active Ceased
- 1997-09-26 AU AU43917/97A patent/AU743820B2/en not_active Ceased
- 1997-09-26 CA CA002266749A patent/CA2266749C/en not_active Expired - Fee Related
- 1997-09-26 DE DE69732419T patent/DE69732419T2/de not_active Expired - Lifetime
- 1997-09-26 WO PCT/GB1997/002629 patent/WO1998013522A1/en not_active Ceased
-
1998
- 1998-09-15 US US09/153,242 patent/US6482592B1/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05501957A (ja) * | 1990-06-11 | 1993-04-15 | ビオ メリウ | サンドウィッチハイブリッド化技術によるヌクレオチド配列の検出方法 |
| JPH0759595A (ja) * | 1992-04-30 | 1995-03-07 | Medical Res Council | 結核菌中のイソニアジド抵抗性の迅速検出 |
| JPH0670799A (ja) * | 1992-08-26 | 1994-03-15 | Toshiba Corp | ハイブリダイゼーション法 |
| JPH06311899A (ja) * | 1993-04-16 | 1994-11-08 | Becton Dickinson & Co | 核酸分析法 |
| JPH0739398A (ja) * | 1993-05-28 | 1995-02-10 | Nippon Flour Mills Co Ltd | 隣接する２種の核酸プローブを用いたｒｎａの検出方法 |
| WO1996013590A2 (en) * | 1994-10-21 | 1996-05-09 | Innogenetics N.V. | New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents |
| JP2002525076A (ja) * | 1998-09-15 | 2002-08-13 | ダイナル エイエスエイ | モジュラーオリゴヌクレオチドによるプライマーエクステンション産物の単離方法 |
Non-Patent Citations (2)
| Title |
|---|
| JPN6008030333, ＢＡＬＡＧＵＥＲ， Ｐ． ｅｔ ａｌ．, ""ｄｅｔｅｃｔｉｏｎ ｏｆ ｓｉｎｇｌｅ ｂａｓｅ ｓｕｂｓｔｉｔｕｔｉｏｎｓ ｉｎ ｐｏｌｙｎｕｃｌｅｏｔｉｄｅｓ ｂｙ ｃａｐｔｕｒｅ ｗｉｔｈ ｉｍｍｏｂｉｌｉｚｅｄ ｏｌｉｇｏｎｕｃｌｅｏｔｉ", Ｍｏｌ． Ｃｅｌｌ． Ｐｒｏｂｅｓ, 1993, Ｖｏｌ．７, ｐｐ．１５５−１５９ * |
| JPN6008030334, ＧＯＴＯＨ， Ｍ． ｅｔ ａｌ．, ""Ａ ｎｅｗ ａｐｐｒｏａｃｈ ｔｏ ｄｅｔｅｒｍｉｎｅ ｔｈｅ ｅｆｆｅｃｔ ｏｆ ｍｉｓｍａｔｃｈｅｓ ｏｎ ｋｉｎｅｔｉｃ ｐａｒａｍｅｔｅｒｓ ｉｎ ＤＮＡ ｈｙｂｒｉｄｉｚａｔｉｏｎ ｕｓｉ", ＤＮＡ Ｒｅｓ．, 1995, Ｖｏｌ．２, ｐｐ．２８５−２９３ * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU743820B2 (en) | 2002-02-07 |
| US6482592B1 (en) | 2002-11-19 |
| DE69732419T2 (de) | 2006-04-06 |
| CA2266749A1 (en) | 1998-04-02 |
| AU4391797A (en) | 1998-04-17 |
| WO1998013522A1 (en) | 1998-04-02 |
| DE69732419D1 (de) | 2005-03-10 |
| ATE288499T1 (de) | 2005-02-15 |
| EP0928342A1 (en) | 1999-07-14 |
| EP0928342B1 (en) | 2005-02-02 |
| CA2266749C (en) | 2009-11-10 |
| ES2234031T3 (es) | 2005-06-16 |
| GB9620075D0 (en) | 1996-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001501470A (ja) | 核酸に基づくアッセイにおけるプローブまたはプライマーとしてのモジュラーオリゴヌクレオチドの使用 | |
| JP2846018B2 (ja) | 核酸配列の増幅および検出 | |
| CN1898395B (zh) | 基于引物的核酸的多重扩增的方法和试剂盒 | |
| KR102592367B1 (ko) | 게놈 및 치료학적 적용을 위한 핵산 분자의 클론 복제 및 증폭을 위한 시스템 및 방법 | |
| JP2021100429A (ja) | 標的核酸の検出方法 | |
| JP2005511030A (ja) | 核酸の増幅方法 | |
| CN102373265B (zh) | 一种检测遗传性耳聋的试剂盒 | |
| WO2005072133A2 (en) | Nucleic acid detection | |
| WO2007106802A2 (en) | Method for linear amplification of bisulfite converted dna | |
| EP2616557B1 (en) | Capture based nucleic acid detection | |
| CN106574304A (zh) | 基于链侵入的dna扩增方法 | |
| CA3021914C (en) | Blood cell lysis reagent | |
| CN104321443A (zh) | Hev测定 | |
| KR20230088272A (ko) | 단일가닥 생성 방법 및 이를 이용한 변이 검출 방법 | |
| TW201802244A (zh) | 建構環狀模板和檢測dna分子的方法 | |
| CA2247545C (en) | Method of isolation of primer extension products with modular oligonucleotides | |
| KR20230087343A (ko) | 단일가닥 생성 방법 및 이를 이용한 변이 검출 방법 | |
| WO2022232683A2 (en) | Multicomponent xnazyme-based nucleic acid detection system | |
| US20250215483A1 (en) | Device, apparatus and method for detecting nucleic acids | |
| JP2024506277A (ja) | 脱塩基核酸を有する配列変換及びシグナル増幅ｄｎａ、並びにそれを使用する検出方法 | |
| AU773108B2 (en) | Method of isolation primer extension products with modular oligonucleotides | |
| KR20250171522A (ko) | 유전자 변이 현장 검출을 위한 등온 단일 반응 프로브 세트 및 이의 용도 | |
| CN119639898A (zh) | 基于无限拉链式杂交链式反应的miRNA检测用组合物、荧光生物传感器及其构建方法与应用 | |
| JP3145169B2 (ja) | 核酸検出法及びキット | |
| JP2001522588A (ja) | 特異的ヌクレオチド配列を検出するための方法および組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040924 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040924 |
|
| A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20070727 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20070727 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080624 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080922 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081027 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081022 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081201 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081121 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081224 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100126 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100423 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100607 |
|
| A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20100816 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100921 |